Today's Rundown ‘Trick or Treat?’ Analysts react to Biogen’s aducanumab surprise Rapt Therapeutics revives IPO, files to raise $75M Novartis bets $80M on Pliant's preclinical NASH prospect [Sponsored] Advancing Site-Sponsor Relationships Evotec brings early stage accelerator model to Israel After phase 3 bust, Lilly cans pancreatic cancer program for Armo buyout drug Amgen CFO David Meline, overseer of major restructuring, to retire Featured Story | | | Wednesday, October 23, 2019 Biogen stunned investors and analysts alike on Tuesday when it said it would file its Alzheimer's medaducanumab for approval, despite canning two phase 3 studies for the drug after a futility analysis. Now that the dust has settled, what are analysts saying? |
|
|---|
|
Top Stories Wednesday, October 23, 2019 Second time might be the charm for Rapt Therapeutics, which filed to raise up to $75 million in its IPO after postponing an earlier attempt in August. This move comes after the company renamed itself and filed its initial S-1 form with plans to reap up to $86 million in its Nasdaq debut. Wednesday, October 23, 2019 Novartis has put up $80 million to land the global license to Pliant Therapeutics’ preclinical nonalcoholic steatohepatitis (NASH) asset and three additional candidates. The NASH drug, PLN-1474, is a small molecule inhibitor of integrin αVβ1 Pliant thinks can reduce the growth of fibrotic tissue in the liver. Monday, October 21, 2019 Clinical trials involve massive complexity and, often, systems that lack consistency and discipline. With a new perspective to an old problem, WCG coordinates the execution of six proven strategies to dramatically and consistently bring clinical studies to launch faster and at a lower cost. Wednesday, October 23, 2019 Evotec has expanded its model for accelerating early-stage academic research to Israel. The creation of the latest outpost of the BRIDGE model sees Evotec team up with Integra Holdings and Yissum to help researchers at the Hebrew University of Jerusalem translate their work. Wednesday, October 23, 2019 Eli Lilly is canning the lead program for the crown jewel of its $1.6 billion Armo Biosciences buyout after the drug put up a poor showing in pancreatic cancer. The Big Pharma said it was ending the phase 3 study of pegilodecakin in its third-quarter earnings presentation. Wednesday, October 23, 2019 In the second half of 2014, Amgen initiated a major overhaul aimed at cutting costs and boosting R&D activities. Now, the chief financial officer tapped on the eve of the revamp is set to bid adieu after successfully turning around the big biotech's financial numbers. | | Better than the other transgenics.
Better than in vitro display.
Better than humanization. AlivaMabTM Mouse from Ablexis delivers quality, speed and value in generating development-ready antibodies that meet your target product profile. Contact us at [email protected] to learn more. ablexis.com |
Resources Sponsored by: Outer Edge Technology Companies that don’t have a cloud strategy are at a competitive disadvantage. Why? The cloud has a measurable impact on business. Sponsored by: Medidata Simplified filing, improved oversight, audit readiness: is your eTMF system delivering best-in-class benefits? Sponsored by: Colorcon® Learn about how you better manage product authentication and battle drug counterfeiting with innovative solutions. Sponsored by: Cortellis, a Clarivate Analytics Solution Download this report for full details of Life sciences M&As in the second quarter of 2019 with notes and trends. Sponsored by: Elligo Health Research Find out how it leverages real-world data and novel IntElligo Research Stack™ technology to help researchers battle rising costs, cumbersome processes, and stagnant participation — bridging the gap between research and care. Sponsored by: InformedDNA Download this complimentary guide paper that explores key strategies for a successful genetics-informed clinical trial. Sponsored by: Life Image The time has finally come when medical imaging can be effectively utilized into the RWE process. Read the whitepaper on the best practices for incorporating Real World Imaging.™ Sponsored by: Patheon, by Thermo Fisher Scientific Is your API development on track? Sponsored by: ON24 Compare digital program performance and audience engagement among your life sciences peers. Sponsored by: Decision Resources Group Clinically Integrated Networks are vehicles for powerful IDNs to extend their influence into the physician sector and play a key role for IDNs trying to pave a path to becoming a self-contained healthcare ecosystem. Sponsored by: Roche and IQVIA A global landscape study of funding trends and innovations. Sponsored by: Catalent Download the case study to learn about the clinical supply management tools that helped a small sized pharma company during phase III of a multi-arm oncology study. Sponsored by: Catalent Watch a short video on demand led supply model. It is designed to meet the needs of patients, clinical sites, clinical team and sponsors and results in shorter lead time, less waste, less stock out risk and no booklet labels. Sponsored by: Catalent Download the eBook to explore a proactive approach for clinical supply management. 4th FierceBiotech Drug Development Forum October 28-29, 2019 | Boston, MA Drug Development Immersion November 7-8, 2019 | Boston, MA Advanced Therapies: Immunotherapies, Cell Therapies and Gene Therapies November 15, 2019 | Boston, MA Countdown to Drug Development Boot Camp® 2019 November 20-21, 2019 | Boston, MA | Register Now at www.drugstomarket.com/drugbootcamp and start Pre-Boot Camp Preparation | 